Reply to B. Freidlin et al.

[1]  Boris Freidlin,et al.  Adaptive randomization versus interim monitoring. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Parmigiani,et al.  Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Ying Yuan,et al.  On the usefulness of outcome-adaptive randomization. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Freidlin,et al.  Outcome--adaptive randomization: is it useful? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Berry.  Adaptive clinical trials: the promise and the caution. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.